Jodie Foster and the cast and crew of The Mauritanian discuss how the film brings Guantanamo back into the spotlight.
Jodie Foster and the cast and crew of The Mauritanian discuss how the film brings Guantanamo back into the spotlight.
New York, New York--(Newsfile Corp. - March 8, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging that the Company violated federal securities laws.Class Period: May 11, 2020 and November 4, 2020Lead Plaintiff Deadline: April 13, 2021Learn more about your recoverable losses in BLUE:http://www.kleinstocklaw.com/pslra-1/bluebird-bio-inc-loss-submission-form?id=13454&from=5The filed complaint alleges that bluebird bio, Inc. made materially false and/or misleading statements ...
"Evie Jo is doing great with her sleeping and eating," Jinger (Duggar) Vuolo says in a new update
The S&P/TSX Composite Index just posted a fresh record high near 18,596 this morning. It could be the best time to make millions from the market if you invest in the right stocks at the right time. Here are two great Canadian tech stocks that just got cheap. The post TSX Rallies to Record High! Best Time to Make Millions From Stocks appeared first on The Motley Fool Canada.
The surge in BK Virus Infection cases spurs treatment opportunities, and many prominent players such as AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and others come forward to develop BK Virus Infection therapies.Los Angeles, USA , March 08, 2021 (GLOBE NEWSWIRE) -- BK Virus Infection Clinical Trials Review: An Update on Emerging Therapies and Treatment The surge in BK Virus Infection cases spurs treatment opportunities, and many prominent players such as AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and others come forward to develop BK Virus Infection therapies. DelveInsight’s “BK Virus (BKV) Infection Pipeline Insight'' report provides comprehensive insights about ...4+ companies and ...4+ pipeline drugs in the BK Virus Infection pipeline landscapes. It comprises BKV Infection pipeline drug profiles, including clinical and non-clinical stage products. It also includes the BK Virus Infection therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive BKV Infection pipeline products. Some of the crucial features of the BK Virus Infection Pipeline Report The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation, and EMA has offered PRIority MEdicines (PRIME) and Orphan Drug (ODD) designations to Viralym-M. The companies such as AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and many others are developing therapies to improve BK Virus Infection treatment scenario. BK Virus Infection pipeline assets such as ALVR-105, MAU868, SL-V10, HYB-BKV, and others are in different developmental stages to treat BKV Infection. The BK Virus Infection pipeline has HYB-BKV (Hybridize Therapeutics) in pre-clinical stage of development, while SL-V10 (SL VAXiGEN) and MAU868 (Amplyx Pharmaceuticals) in phase I and Phase II of clinical development respectively. Teriflunomide by Sanofi Genzyme is in the preclinical stage of development for the treatment of Human polyomavirus infections. Request for sample pages @ BK Virus Infection Clinical Trial Insight BK is a circular, double-stranded DNA virus from the polyomavirus family, including the JC virus and SV40. BK virus is one of 13 known polyomaviruses. Antibodies to BKV are available in around 80 to 90 percent of adults globally, indicating previous infection or exposure to the virus. Initial infection with BKV is mostly asymptomatic or associated with a mild flu-like illness. After primary infection, BK Virus Infection continues to be inactive or latent in the kidney and bladder. A weakened immune system may lead to BKV reactivation and cause severe disease. In patients who have had kidney transplants, BK Virus Infection can result in transplanted kidney loss. In the absence of effective treatment, decreasing immunosuppression is recommended; but, reducing the immunosuppression can result in acute organ rejection. BKV reactivation in the bladder can lead to hemorrhagic cystitis. Severe cases need bladder irrigation, clot evacuation, blood transfusion, stenting, and nephrostomy. There are presently no approved treatments for renal nephropathy or hemorrhagic cystitis caused by BK Virus Infection. The backbone of treatment for BK virus nephropathy is to lower the immunosuppression, as there is currently no particular antiviral for the BK virus. Clearance of BK viremia can be a sign of nephropathy resolution. BKV Pipeline Drugs Viralym-M by AlloVir ALVR 105 is a human leukocyte antigen (HLA) matched multi-virus-specific T cell candidate, also known as Viralym-M, developed by AlloVir. Viralym-M is designed to function an essential role in linking immunity between conditioning and reconstitution of their immune systems. Reinstituting immunity during this time of critical immune compromise, Viralym-M may substantially decrease or prohibit virus-associated morbidity and mortality and dramatically enhance patient results. Viralym-M has the potential to transform care for transplant patients fundamentally, as well as people who are at high risk for opportunistic viral infections by decreasing or preventing disease morbidity and dramatically improving. Research and Development Phase III NCT04390113: AlloVir commenced a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the treatment of patients with Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Cell Transplant (HCT) in January 2020. The study aims to assess Viralym-M, an allogeneic, off-the-shelf multi-virus-specific T cell therapy, which focuses on six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. The study hypothesis is to administer Viralym-M to patients with virus-associated HC will show superiority for the time to resolution of HC as compared to patients when treated with placebo. The primary hypothesis will be evaluated in patients with BK virus viruria to show superiority over placebo in this population (BK Intent-to-Treat [ITT] population). A supplementary analysis will be carried out in all patients with any virus-associated HC (cytomegalovirus [CMV], human herpesvirus 6 [HHV-6], Epstein-Barr virus [EBV], JC virus [JCV], and/or adenovirus [AdV]) to assess the efficacy in this broader population (ITT Population). The study is anticipated to be finished by August 2022. For further product profiles, request @ BK Virus Infection Pipeline Landscape Scope of BKV Infection Pipeline Drug Insight Coverage: Global Major Players: 4+ Key Players Prominent Players: AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and many others. Key Drugs Profiles: 4+ Products Phases: BKV Infection Therapies Late-stage (Phase III) BK Virus Infection Therapies (Phase II) BKV Infection Therapies (Phase I) BK Virus Infection Therapies Pre-clinical stage and Discovery candidates Discontinued and Inactive candidates Targets: Protease Immune System Multiple Kinase Route of Administration: Intramuscular Intravenous Oral Subcutaneous Mechanism of Action: Immunostimulants Antisense oligonucleotides Antibody-dependent cell cytotoxicity; Immunomodulators Immunologic cytotoxicity; T lymphocyte replacements Molecule type: Monoclonal antibodies Stem Cell Therapy DNA Vaccines Product Type Monotherapy Combination Key Questions regarding Current BK Virus Infection Treatment Landscape and Emerging Therapies Answered in the Pipeline Report What are the current options for BK Virus Infection treatment? How many companies are developing therapies for the treatment of BK Virus Infection? How many are BK Virus Infection emerging therapies in the early-stage, mid-stage, and late stages of development to treat BK Virus Infection? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the BK Virus Infection market? Which are the dormant and discontinued products and the reasons for the same? What is the unmet need for current therapies for the treatment of BK Virus Infection? What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing BK Virus Infection therapies? What are the key designations that have been granted for the emerging therapies for BK Virus Infection? How many patents are granted and pending for the emerging therapies for the treatment of BK Virus Infection? Table of Contents 1BK Virus Infection Report Introduction2BK Virus Infection Executive Summary3BK Virus Infection Overview4BK Virus Infection Analytical Perspective In-depth Commercial Assessment5BK Virus Infection Pipeline Therapeutics6BK Virus Infection Late Stage Products (Phase III)6.1ALVR-105: AlloVir7BK Virus Infection Mid Stage Products (Phase II)7.1MAU868: Amplyx Pharmaceuticals8BK Virus Infection Early Stage Products (Phase I)8.1SL-V10: SL VAXiGEN9BK Virus Infection Pre-clinical Products and Discovery Stage Products9.1HYB-BKV: Hybridize Therapeutics10BK Virus Infection Therapeutic Assessment11BK Virus Infection Inactive Products12Company-University Collaborations (Licensing/Partnering) Analysis13BK Virus Infection Key Companies14BK Virus Infection Key Products15 BK Virus Infection Unmet Needs16BK Virus Infection Market Drivers and Barriers17BK Virus Infection Future Perspectives and Conclusion18BK Virus Infection Analyst Views19Appendix20About DelveInsight Get customized pipeline report @ BK Virus Infection Drug Treatment Related Reports BK virus (BKV) Infection Market DelveInsight's BK virus (BKV) Infection - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. BK virus (BKV) Infection Epidemiology Forecast DelveInsight's BK virus (BKV) Infection - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of BK virus (BKV) Infection in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Adeno-Associated Virus Vectors in Gene Therapy Market DelveInsight's "Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology. Chronic Hepatitis B Virus Market DelveInsight's Chronic Hepatitis B Virus- Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. Chronic Hepatitis Delta Virus (HDV) Infection Market DelveInsight's Chronic Hepatitis Delta Virus (HDV) Infection - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Epstein Barr Virus (EBV) Market DelveInsight's Epstein Barr virus (EBV) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur firstname.lastname@example.org +1(919)321-6187 www.delveinsight.com
A second member of the regulator that oversees Texas' utilities resigned on Monday in a continuation of the political fallout over a weather-driven crisis in the state's power market. Shelly Botkin resigned effective immediately, the Public Utility Commission of Texas said in a one sentence notice. Electricity and natural gas prices surged as an arctic air mass brought subzero temperatures, killing dozens of people and leaving much of its power market in the throes of a deep financial crisis.
His personal wealth soared as the video conferencing platform became a household name during the pandemic.
Mike Foltynewicz is almost as perplexed about how quickly his velocity has returned this spring with the Texas Rangers as the former All-Star was about how quickly it went away last summer when his former team gave up on him. The right-hander peeked at the scoreboard after the first pitch of his spring training debut Monday with Texas and saw 95 mph. He also hit 96-97 mph on other pitches. “Last year, I just literally don’t know what happened,” Foltynewicz said. “I kept throwing and I kept doing everything I needed to do. And I just don’t know what happened. So for all of this to play out right now ... just to see those numbers, yes, it’s very assuring, and that tick of confidence goes up a little bit more.” For both Foltynewicz and the pitching-needy Rangers, who unlike the playoff-bound Atlanta Braves in the shortened season last summer, have some time to find out if the 29-year-old right-hander is getting back to form. Those two perfect innings against the defending World Series champion Los Angeles Dodgers on Sunday in Arizona were an encouraging first step. “That exceeded my expectations,” manager Chris Woodward said. “It meant the world to him to kind of get back out there and, you know, resemble his old self. And it was easy. It wasn’t like he was trying to force it to be 95, 96 (mph). It just was natural. It’s just the way his body was moving, which it had in the past.” Foltynewicz has added back at least 10 pounds to his lanky 6-foot-4 frame, regaining some strength lost during baseball's shutdown because of the pandemic that started in spring training and lasted about four months. In his only start once the season began, he allowed six runs, three homers and four walks in 3 1/3 innings with a flat fastball at around 90 mph. The Braves designated him for assignment after that 14-5 loss to Tampa Bay, sent him to their alternate site when he wasn't claimed off waivers and didn't offer a new contract after the season. While a bit surprised by the move last summer, Foltynewicz said he understood the Braves were trying to win a championship in a short season — they did get to the NL Championship Series played at the Rangers' new ballpark, and he was there without playing. “They gave me plenty of chances in the past,” he said. “It's a business, I get all of that part of it. But in the back of the mind, it kind of fuels you a little bit when someone gives up on you like that.” An All-Star in 2018, when he was 13-10 with a 2.85 ERA in 31 regular-season starts, Foltynewicz was sent back to Triple-A midway through the 2019 season to work out some early-season issues. He finished strong after getting called back up, then pitched seven scoreless innings against St. Louis in Game 2 of the NL Division Series. But he also started the deciding Game 5 when the Cardinals had a 10-run first inning. Foltynewicz signed a $2 million, one-year contract with Texas just before the start of spring training and is not eligible for free agency until after the 2022 season. Even though Foltynewicz was throwing and running every day when players were away from their teams last year, with gyms closed and lacking certain equipment, he wasn't able to maintain his strength by doing squats and other weights workouts. The impact was obvious, though Foltynewicz and the Rangers said explaining his regained velocity now isn't just as simple as regained strength. “There’s so much more than that,” Woodward said. While Foltynewicz made adjustments to his eating habits and lifestyle, there was also the biomechanical and analytical approach Rangers pitching coaches presented to him even before he signed with them. “Basically diagnosing some of the problems or the things that they could help fix, I think that’s what really set maybe us apart from other teams in his mind,” Woodward said. “And you see the impact that it’s had already. His first outing was it was beyond what I even expected. I was expecting it to be decent, but that was pretty dominant.” It was the kind of velocity that made Foltynewicz successful in the past, since all of his other pitches — slider, changeup and curveball — then work off that. After that initial 95 mph pitch which got out Mookie Betts on a flyball, Foltynewicz said he was able to take a deep breath and then attack hitters and use all of his stuff. “You get weak contact, strikeouts, whatever it may be, and you just have fun," he said. ”You start having fun again in the game of baseball." ___ More AP MLB: https://apnews.com/hub/MLB and https://twitter.com/AP_Sports Stephen Hawkins, The Associated Press
New York, New York--(Newsfile Corp. - March 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Astrazeneca Plc ("Astrazeneca") (NYSE: AZN) between May 21, 2020 and November 20, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more ...
The Republican Party intends to keep using former President Donald Trump's name in fundraising pitches and other materials, a lawyer for the party said on Monday, despite a cease-and-desist letter from Trump last week. The letter sent by lawyers for Trump on Friday to the Republican National Committee, National Republican Congressional Campaign and National Republican Senate Campaign had ramped up tension between the two camps as Trump seeks to preserve his political viability post-election. A Trump adviser said on Saturday that Trump was sensitive to the use of his name and likeness for branding purposes and was irked the three groups have supported Republican lawmakers who joined Democrats in voting to impeach him over the Jan. 6 storming of the U.S. Capitol by pro-Trump protesters.
Thousands of Paraguayans gathered around Congress in downtown Asunción on Monday, marking the fourth day of protests amid calls to impeach President Mario Abdo over the government's handling of the COVID-19 health crisis. The protesters, many wearing soccer jerseys and carrying national flags, chanted "Out Marito" and "Everyone out", while criticizing the authorities for the lack of medicines and intensive care beds amid a spike in coronavirus cases. "In the hospitals there are no syringes, there are no beds," a young man who identified himself as Dudu Dávalos told local television after traveling from the city of Hernandarias, 340 km (210 miles) east of Asunción.
Now that Hyundai has shown its E-GMP electric car with the creased Ioniq 5, it's Kia's turn to show what it can do. The first of its E-GMP cars is called the EV6, and we're getting our first clear glimpse of it with these teaser images. From what we can see, it looks drastically different from the Hyundai.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, March 08, 2021 (GLOBE NEWSWIRE) -- Eloro Resources Ltd. (the “Company” or “Eloro”) (TSX-V: ELO; OTCQX: ELRRF; FSE: P2QM) is pleased to announce that, in connection with its previously announced bought deal financing (see Eloro press releases dated March 2, 2021 and March 3, 2021), it has filed a preliminary short form prospectus with the applicable securities regulators in each of the provinces of Canada, except Quebec. Under the terms of the financing, Haywood Securities Inc. and Cantor Fitzgerald Canada Corporation as co-lead underwriters and joint-bookrunners, and Cormark Securities Inc. as co-lead underwriter (collectively, the “Underwriters”) have agreed to purchase, on a bought deal basis, 5,800,000 units (the “Units”) at a price of C$3.75 per Unit (the “Issue Price”) for gross proceeds to the Company of C$21,750,000 (the “Offering”). Each Unit will consist of one common share (a “Common Share”) in the capital of the Company and one-half (1/2) of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”) of the Company. Each Warrant shall be exercisable to acquire one Common Share (a “Warrant Share”) at a price per Warrant Share of C$5.25 for a period of 24 months from the closing date of the Offering. The expiry date of the Warrants may be accelerated by the Company at any time following the six-month anniversary of the closing date of the Offering and prior to the expiry date of the Warrants if the volume-weighted average trading price of the Company’s Common Shares is greater than C$7.00 for any 20 consecutive trading days, at which time the Company may accelerate the expiry date by issuing a press release to announce the reduced warrant term, whereupon the Warrants will expire on the 20th calendar day after the date of such press release. In addition, the Company has agreed to grant to the Underwriters an option to purchase up to an additional 15% of the number of Units sold under the Offering at a price per Unit equal to the Issue Price, on the same terms and conditions as the Offering, exercisable at any time, in whole or in part, until the date that is 30 days following the closing of the Offering. The Company intends to use the net proceeds from the Offering mainly for continued exploration and development of the Company’s Iska Iska project in Bolivia. To March 3, 2021, a total of 7,539 metres of diamond drilling has been completed in 12 underground holes from the Huayra Kasa workings and 11 surface holes at Iska Iska. On February 16, 2021, Eloro announced the addition of a second drill rig to commence drilling on the Central Breccia Pipe target. Planned diamond drilling for the balance of 2021 and Q1 2022 is 51,000 metres, comprising 6,000 metres already budgeted and an additional 45,000 metres planned to be funded from the Offering. Additional drills will be added in stages so that by July 2021, 4 surface drill rigs are expected to be operating with an expected production of 6,000 metres per month. This drilling will be done to explore and define a mineral resource in the Santa Barbara Breccia Pipe, Central Breccia Pipe, South Porco Breccia Pipe target and the Huayra Kasa Breccia Pipe and underground workings. Included as part of the 45,000 metres are 6,000 metres of drilling in outside targets at Iska Iska and the Pache property located 20 kilometres southwest of Iska Iska. Eloro also intends to pay from the proceeds of the Offering US$2,500,000 toward the US$10,000,000 option price under an option agreement to acquire a 99% interest in the Iska Iska Project. The Offering is scheduled to close on or about March 26, 2021 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals including the approval of the TSX Venture Exchange and the securities regulatory authorities. The preliminary short form prospectus is still subject to completion or amendment. A copy of the preliminary short form prospectus is available electronically at www.sedar.com. There will not be any sale of or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued. The securities offered in the Offering have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Qualified Person Dr. Bill Pearson, P.Geo., Eloro’s Executive Vice President Exploration and a Qualified Person as such term is defined in National Instrument 43-101, has reviewed and approved the technical content of this news release. About Eloro Eloro is an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Eloro has an option to acquire a 99% interest in the highly prospective Iska Iska Property, which can be classified as a polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department, in southern Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR. Iska Iska is a road-accessible, royalty-free property. Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru some 50 km south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometres. La Victoria has good infrastructure with access to road, water and electricity and is located at an altitude that ranges from 3,150 m to 4,400 m above sea level. For further information please contact either Thomas G. Larsen, Chairman and CEO, or Jorge Estepa, Vice President at (416) 868-9168. Information in this news release may contain forward-looking information. Statements containing forward-looking information express, as at the date of this news release, the Company’s plans, estimates, forecasts, projections, expectations, or beliefs as to future events or results and are believed to be reasonable based on information currently available to the Company (forward-looking statements in this news release include, without limitation, statements regarding the completion of the Offering, the use of proceeds from the Offering and the Company’s exploration plans at the Iska Iska property). There can be no assurance that forward-looking statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
NEW YORK — It wasn’t “You get a car!” but Oprah Winfrey gave TV executive Jesse Collins something equally, if not even more, cool: “You get to produce the Oscars!” Emmy-nominated Collins has had success over the years with the BET Awards, the Grammy Awards and various TV specials, and now he’s bringing his magical touch to the 2021 Academy Awards, thanks to a co-sign from the queen of all media. “I got an email from Oprah saying, ‘What’s your cell?,’” Collins recalled to The Associated Press. “She had a conversation with Bob Iger and Disney, and she had recommended me for the Oscars. “It’s interesting because (the Academy and I) had met in previous years but then this was the year. I think the Oprah stamp definitely helped push it,” he added. “It’s like the greatest reference you could ever have. You know, on a job reference you put your mom and your best friend who you know won’t say something stupid and your cousin, who also has a good job. Oprah trumps all of that.” Collins’ Oscars gig will come weeks after the March 14 Grammys — this year he's been promoted to co-executive producer — and two months after he became the first Black executive producer of the Super Bowl halftime show. “I did not expect them to all line up like this,” he said. “It’s a once-in-a-lifetime moment.” He’s the busiest and most-requested man in showbiz. The 50-year-old is the CEO of Jesse Collins Entertainment, the production company he founded in 2012. He earned an Emmy nomination for producing the 2019 Grammys, and he’s had major success with the Soul Train Awards, Netflix’s “Rhythm + Flow,” “Black Girls Rock!” and the three-part “The New Edition Story,” which pulled in record ratings for BET in 2017. He and his all-star team hit new heights with last year’s BET Awards, one of the first awards shows produced during the pandemic. The event was a critical success, as Collins and producers put together a show featuring highly produced and well-crafted pre-taped performances, with some centred around the Black experience highlighted by the Black Lives Matter movement, civil rights and the lives of those lost because of police officers, including George Floyd. “I think the BET Awards were a jumping off point for a lot of stuff. All of a sudden people just wanted to know how we did it and what made us go that way. The phone definitely lit up the day after we did the show,” he said. One of those calls came from Desiree Perez, the CEO of Roc Nation, Jay-Z's entertainment company that started producing the halftime show last year. “It was life changing to work on something so prestigious with so much history,” Collins said of the spectacle starring The Weeknd. “Just to see how the machine works that pulls that thing together was amazing. Now I understand how the mechanics of a halftime show work. It’s not like anything else.” Next is the Grammys, which were originally supposed to take place on Jan. 31 but were delayed due to the pandemic. It will mark Collins' 10th year working on the show, where he's held positions like segment producer, consulting producer and producer. Performers include Taylor Swift, Cardi B, BTS, Billie Eilish, Megan Thee Stallion and Harry Styles. “It’s going to be entertaining. It’s going to be everything we need it to be at this moment,” he said. “That’s what we’ve been focused on and that’s what we’re going to deliver.” Collins has a long history of working directly with musicians and booking A-listers for big events. He’s collaborated with Cardi B on both “Cardi Tries” on Facebook Watch and “Rhythm + Flow.” The latter series was a 2019 hit for Netflix, and the winner of the show — bilingual rapper D Smoke — is competing for two Grammys, including best rap album and best new artist. “Rhythm + Flow” contrasts recent seasons of “American Idol” and “The Voice,” where its winners find little success and the spotlight remains on the celebrity judges. “It’s a testament to the show,” Collins said, adding that he hopes the series gets renewed for a second season. “We really wanted to create a show where the show would become a steppingstone for the artist to go on and have a legit career.” But the show will have to wait until Collins' schedule clears up. Just hours after he wraps the Grammys, the nominees for the Oscars will be announced: “That’s when it’s like a horse race. The three of us (producers) are coming out the gate.” Collins is the fourth Black producer in the show's 93rd history, and soon after the April 25 event celebrating the year’s best in film, he would have completed his trifecta. And then he can rest. Sort of. “When the Oscars are over, we’re going right into BET Awards,” he said of the event that typically airs in June. “I think I’ll go on vacation to my couch. I’m going to take a strong nap, like a nice old person nap where you say it’s only going to be 15 minutes and you wake up a day later.” Mesfin Fekadu, The Associated Press
The slower growth was mainly due to a sharper contraction in private inventories and capital expenditure expanding less than previously thought in the fourth quarter, even as exports remained solid. Separate data showed household spending was hit by a bigger annual drop in January than in the prior month, a sign the COVID-19 pandemic was keeping consumers cautious about shopping. Private inventories, including raw materials and manufactured products, subtracted 0.6 percentage point from revised growth domestic product growth (GDP), worse than a negative preliminary contribution of 0.4 percentage point.
The Dallas Cowboys will officially announced a long-term contract with quarterback Dak Prescott on Wednesday.
Leon Gast, the veteran filmmaker who won a Documentary Feature Oscar for helming the 1996 “Rumble in the Jungle” pic When We Were Kings, died Monday. He was 85. The news was confirmed by the Woodstock Film Festival, of which Gast was a founding advisory board member and a 2016 Lifetime Achievement Award honoree. Gast […]
When a huge earthquake and tsunami struck Japan on March 11, 2011, devastating towns and triggering nuclear meltdowns in Fukushima, a stunned world watched the chaotic struggle to contain the world's worst nuclear disaster since Chernobyl. At the time, some - including Prime Minister Naoto Kan - feared Tokyo would need to be evacuated, or worse. "Fukushima is stamped for the rest of the history of nuclear energy," said Kiyoshi Kurokawa, head of an investigation that concluded the disaster was "profoundly man-made".
Prescott got off to a sensational start last season before suffering a gruesome injury in Week 5, fracturing and dislocating his right ankle. The 27-year-old, who was selected by the Cowboys in the fourth round of the 2016 draft, is expected to be fully recovered by the start of next season. "When your little brother gets the call," Prescott's brother Tad posted on Twitter with a photo of the two men hugging.
RADNOR, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Velodyne Lidar, Inc. (NASDAQ: VLDR, VLDRW) (“Velodyne”) on behalf of those who purchased or acquired Velodyne securities between November 9, 2020 and February 19, 2021, inclusive (the “Class Period”). Investor Deadline Reminder: Investors who purchased or acquired Velodyne securities during the Class Period may, no later than May 3, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at email@example.com; or click https://www.ktmc.com/velodyne-lidar-inc-securities-fraud-class-action?utm_source=PR&utm_medium=link&utm_campaign=velodyne According to the complaint, Velodyne provides solutions to develop safe automated systems including real-time surround view lidar sensors. Velodyne became a public entity on September 29, 2020 when it merged with Graf Industrial Corp., a special purpose acquisition company. The Class Period commences on November 9, 2020, when Velodyne filed its quarterly report on a Form 10-Q with the U.S. Securities and Exchange Commission for the period ended September 30, 2020. The report stated “[b]ased on the evaluation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.” However, the truth began to be revealed on February 22, 2021, before the market opened, when Velodyne announced that its Board of Directors had “removed David Hall as Chairman of the Board and terminated Marta Hall’s employment as Chief Marketing Officer of the Company” after the Audit Committee’s investigation “concluded that Mr. Hall and Ms. Hall each behaved inappropriately with regard to certain Board and Company processes, and failed to operate with respect, honesty, integrity, and candor in their dealings with [Velodyne] officers and directors.” In addition, Velodyne’s Board formally censured Mr. Hall and Ms. Hall, but they would remain directors of Velodyne. Following this news, Velodyne’s common stock fell $3.14, or approximately 15%, to close at $17.97 per share on February 22, 2021. Additionally, Velodyne’s warrants fell $1.47, or approximately 20%, to close at $5.90 per warrant on February 22, 2021. The complaint alleges that throughout the Class Period, the defendants failed to disclose to investors that: (1) certain of Velodyne’s directors had failed to operate with respect, honesty, integrity, and candor in their dealings with Velodyne’s officers and directors; (2) Velodyne was investigating the foregoing matters; and (3) as a result of the foregoing, the defendants’ positive statements about Velodyne’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Velodyne investors may, no later than May 3, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP, prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. CONTACT:Kessler Topaz Meltzer & Check, LLPJames Maro, Jr., Esq.Adrienne Bell, Esq.280 King of Prussia RoadRadnor, PA 19087(844) 887-9500 (toll free)firstname.lastname@example.org
VANCOUVER — British Columbia's health minister promised to "do better" on Monday after call centres to schedule vaccine appointments were overwhelmed on the first day of booking. Adrian Dix said there were 1.7 million calls in less than three hours after the phone lines opened for people over 90 and Indigenous elders over 65 to book their appointments. Dix said he believed that people who were not yet eligible for the COVID-19 vaccine were flooding the lines, but he also acknowledged that more staffing was needed. "It's really important in order to allow those over 90 to get their appointments that we only call when our age group becomes open for calling," he told the province's COVID-19 briefing. "It's also important that we do better. I know that people have called in and have waited a long time today." Dix said that more resources would be added in the coming weeks, as more age groups become eligible to call to book their vaccines. People born in 1936 or earlier can start calling for appointments on March 15 and those born in 1941 or earlier can start to schedule their immunizations March 22. Fraser Health was the only authority to launch an online booking platform on Monday, but Dix said a web-based system would become widely available on April 12. Some residents with elderly parents said they spent hours redialing their health authority's number and only got a busy signal or a recorded message telling them to call back later. Julie Tapley, whose 90-year-old father lives in the Vancouver Coastal Health region, said she was frustrated that the authority had not yet established an online booking system. "I just want to get in the queue and start the process so that (my parents) can return to their normal lives." B.C.'s provincial health officer, Dr. Bonnie Henry, said creating an online booking system is "quite a large project" and Fraser Health was the only authority with an existing platform. Of about 80,000 people eligible to book appointments this week, roughly 26,000 have already received a shot, so a relatively small number of people should be calling, Dix said. He said about 10,000 appointments were booked as of Monday afternoon and a "significant number" of those were scheduled through the Fraser Health online site. Dix urged eligible residents and their families to keep calling in the coming days. There are plenty of appointments available and it is not a "first-come, first-serve" system, he said. Although B.C.'s case numbers have been on the rise, Henry said some restrictions would be eased in the coming weeks as the weather warms and immunizations ramp up. Outdoor gatherings, larger meeting places and layers of protection such as masks will still be recommended, she said. "I like to think of it as slowly turning up the dial again rather than flicking a switch," she said. She also said she hopes to see the return of sports and in-person religious ceremonies within weeks. Officials have been developing a plan with faith leaders to enable the gradual return of in-person services, as there are important dates in many religions coming up, Henry said. A B.C. Supreme Court judge reserved his decision on Friday on a petition filed by three Fraser Valley churches who argued that a ban on in-person services violates charter rights. Henry reported on Monday 1,462 new COVID-19 cases and 11 deaths over three days, pushing the death toll to 1,391 in the province. She said there was one new outbreak in a long-term care home, the Cottonwoods Care Centre in Kelowna, where a high number of residents and staff had already been vaccinated. The flare-up serves as a reminder that while vaccines are effective and prevent severe illness and death, they don’t necessarily mean that all transmission will be stopped, she said. There have been 144 new cases that are variants of concern, bringing the total to 394 confirmed cases. Officials still do not know how about a quarter of the cases were acquired. Henry became emotional when quoting Chief Robert Joseph, a knowledge-keeper with the Assembly of First Nations. "We will celebrate our lives again, dream our dreams again and watch our children regain their hope," Henry quoted him as saying, with tears in her eyes. "That's what we can look forward to in the coming months." This report by The Canadian Press was first published March 8, 2021. Laura Dhillon Kane, The Canadian Press